- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02343575
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford Hospital and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients 18 years of age and older
- admitted to surgical ICU
- diagnosed with hyperactive or mixed delirium
Exclusion Criteria:
- hypoactive delirium
- primary team does not think patient is appropriate to participate
- no oral access (PO or NGT)
- non-English speaking
- contraindication to study medications
- pregnant women or woman of child-bearing age not on documented contraception
- QTc = or greater than 480
- hepatic dysfunction
- decreased platelets or platelet dysfunction
- bleeding disorder, current major bleeding
- history of NMS, epilepsy, or PD
- diagnosis of schizophrenia, bipolar disorder or schizoaffective disorder
- on warfarin or carbapenems
- delirium due to alcohol withdrawal
- treated with antipsychotics for more than 48 hours prior to study enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Valproic Acid
VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS Rescue at all stages: HAL IV 2-5 mg Q4hr PRN |
1. Start: VPA PO/NGT 500 mg BID 2. If need to increase in 24 or more hours: VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS 3. If need to increase in 24 or more hours: VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS 4.If need to increase in 24 or more hours: VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
Other Names:
Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
Other Names:
|
Placebo Comparator: Placebo
Placebo: PO/NGT BID Rescue: HAL IV 2-5 mg Q4hr PRN |
Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
Other Names:
Placebo 500 mg matched to VPA BID PO/NGT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Delirium Resolution
Time Frame: Up to 5 days
|
Delirium resolution was defined as three negative Confusion Assessment Method (CAM) assessments, performed by nurses every 12 hours.
|
Up to 5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of as Needed Anti-psychotic Agent
Time Frame: Up to 5 days
|
Amount of Haldol administered.
|
Up to 5 days
|
Side Effects From Medications
Time Frame: Up to 5 days
|
Side effects may have included liver function test (LFT) increase, platelet decrease, bleeding, or QTc prolongation.
|
Up to 5 days
|
Intensity of Delirium as Measured by the Intensive Care Delirium Screening Checklist (ICDSC) Delirium Severity Scale
Time Frame: Up to 5 days
|
The items include the assessment of: (1) consciousness ( deep sedation/coma, agitation, normal wakefulness, or light sedation); (2) inattention; (3) disorientation; (4) hallucination, delusion, or psychosis; (5) psychomotor agitation or retardation; (6) inappropriate speech or mood; (7) sleep-wake cycle disturbances; and (8) fluctuation of symptomatology.
The maximum score is eight; scores of ≥4 indicate the presence of delirium and score zero is indicate not in delirium.
Each item is scored 0-8.
|
Up to 5 days
|
Length of ICU Stay
Time Frame: During expected average hospitalization (of 1 month)
|
During expected average hospitalization (of 1 month)
|
|
Length of Hospital Stay
Time Frame: During expected average hospitalization (of 1 month)
|
Participation in the study ended once delirium was resolved and the patient was off study drug.
This outcome presents the total length of hospital stay, which may have been longer than participation in the study.
|
During expected average hospitalization (of 1 month)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yelizaveta Sher, M.D., Stanford University
- Study Director: Jose R Maldonado, M.D., Stanford University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Dyskinesias
- Psychomotor Disorders
- Delirium
- Psychomotor Agitation
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Anti-Dyskinesia Agents
- Valproic Acid
- Haloperidol
- Haloperidol decanoate
Other Study ID Numbers
- 28330
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperactive Delirium
-
Stanford UniversityCompletedHypoactive Delirium | Hyperactive Delirium | Mixed Type DeliriumUnited States
-
Simon Fraser UniversityUnknownHyperactive Delirium
-
Alexandria UniversitySuez Canal University; Gezira UniversityCompleted
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Bruyere Research InstituteThe Ottawa Hospital; Foothills Medical Centre; Bruyère Continuing CareRecruitingDelirium of Mixed Origin | Hyperactive DeliriumCanada
-
Tan Tock Seng HospitalRecruitingAdvanced Cancer | Hyperactive Delirium | Olanzapine | Haloperidol | End-stage Organ DiseaseSingapore
-
M.D. Anderson Cancer CenterCompleted
-
University of MiamiWithdrawnPneumonia, Viral | Covid19 | Hyperactive DeliriumUnited States
-
Sync-Think, Inc.Sutter HealthUnknownADHD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - ImpulsiveUnited States
-
Fundacion para la Formacion e Investigacion Sanitarias...Unknown
Clinical Trials on Valproic Acid
-
New Mexico Cancer Care AllianceCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
New Mexico Cancer Care AllianceWithdrawnChronic Myelogenous LeukemiaUnited States
-
University of Sao PauloCompletedParaparesis Spastic TropicalBrazil
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System TumorsCanada, United States
-
Northwell HealthTerminatedHealthy | Obesity | PharmacokineticsUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompleted
-
Nantes University HospitalCompletedProgressive Supranuclear PalsyFrance
-
Johns Hopkins UniversityNational University Hospital of SingaporeWithdrawnNasopharyngeal CarcinomaSingapore